ARTICLE | Clinical News
Aldeyra Therapeutics preclinical data
May 26, 2014 7:00 AM UTC
In reconstructed human epidermis under dry skin conditions, topical 0.05% NS2 significantly reduced malondialdehyde (MDA) levels vs. untreated controls (p<0.01). Aldeyra said that MDA levels have been shown to be elevated in a variety of inflammatory skin and eye diseases. An eye drop formulation of 0.5% NS2 also significantly reduced MDA levels in reconstructed human cornea-like tissue under dry eye conditions vs. untreated controls (p<0.01). Data were presented at the Society for Investigative Dermatology meeting in Albuquerque. ...